MacroGenics, Boehringer Ingelheim deal

Boehringer and MacroGenics will use MacroGenics' Dual-Affinity Re-Targeting (DART) platform to discover bi-specific antibody therapeutics against up to 10 combinations of molecular targets in multiple areas, including immunology, cancer, respiratory, cardiometabolic and infectious disease indications. The partners will jointly collaborate on discovery and certain preclinical activities, while Boehringer will be responsible for further development and commercialization. ...